Limited data have examined REG3A in the context of stroke pathology; however, increased REG3A has previously been identified as a biomarker in inflammation-driven pathologies such as GVHD and gastrointestinal carcinomas [26,27,28]. This evidence concerns the gene REG3A and digestive system carcinoma.